Next Article in Journal
Computer-Aided Drug Design and Synthesis of Rhenium Clotrimazole Antimicrobial Agents
Previous Article in Journal
Molecular Characterization and Epidemiology of Antibiotic Resistance Genes of β-Lactamase Producing Bacterial Pathogens Causing Septicemia from Tertiary Care Hospitals
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antimicrobial Resistance Molecular Mechanisms of Helicobacter pylori in Jordanian Children: A Cross-Sectional Observational Study

1
Department of Pediatrics and Neonatology, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan
2
Department of Basic Medical Sciences, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan
3
Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan
4
Department of Pediatrics, King Hussein Cancer Center, Amman 11941, Jordan
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(3), 618; https://doi.org/10.3390/antibiotics12030618
Submission received: 18 February 2023 / Revised: 7 March 2023 / Accepted: 7 March 2023 / Published: 20 March 2023

Abstract

:
Background: H. pylori antimicrobial resistance causes increasing treatment failure rates among H. pylori gastritis in children. This study investigates the molecular mechanisms of H. pylori antimicrobial resistance among Jordanian children. Methods: Demographic, clinical, and laboratory data were recorded for children referred to Prince Hamzah Hospital. Clarithromycin, Metronidazole, and Levofloxacin susceptibility were tested via E-test. Clarithromycin-related mutations were investigated using Real-Time (RT)-PCR and Levofloxacin resistance was analyzed with DNA sequencing of the gyrA gene. Results: 116 children were recruited, including 55.2% females and 55.2% in the age range of 10.1 to 14 years. A total of 82.7% were naïve to eradication therapy. H. pylori positivity was 93.9%, 89.6%, 61.7%, and 84.3% according to Rapid Urease Test, histology, culture, and RT-PCR, respectively. Resistance rates were 25.9% for Clarithromycin, 50% for Metronidazole, and 6.9% for Levofloxacin via E-test. A2142G or A2143G or a combination of both mutations concerning Clarithromycin resistance were documented in 26.1% of samples, while mutations in gyrA gen-related to Levofloxacin resistance were reported in 5.3% of samples. Antibiotic resistance was significantly affected by abdominal pain, anemia, hematemesis, and histological findings (p < 0.05). Conclusion: H. pylori resistance was documented for Metronidazole and Clarithromycin. RT-PCR for H. pylori identification and microbial resistance determination are valuable alternatives for cultures in determining antimicrobial susceptibility.

1. Introduction

Helicobacter pylori (H. pylori) is a spiral, Gram-negative, rod, curved, microaerophilic bacteria. It has multiple flagella, which play a crucial role in its motility and invasion mechanisms [1]. It was discovered in the human stomach in 1982 by Marshall and Warren, earning them the Nobel Prize for Medicine [1]. Typically, H. pylori infections are acquired during childhood and persist throughout life. It can cause chronic gastritis and gastroduodenal ulcers. Moreover, it is a significant risk factor for gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [2,3,4]. Its eradication effectively reduces the incidence of these malignant pathologies [2,5,6].
H. pylori is usually acquired in childhood, and the reinfection rate in children after its successful eradication is higher than in adults. However, compared to adults, children and adolescents with H. pylori infection rarely present with severe symptoms or develops serious pathologies [3,7].
The management of H. pylori gastritis can include various treatments such as using proton pump inhibitors (PPIs), antibiotics, bismuth, and probiotics. However, the number of antibiotics appropriate for H. pylori eradication in children is limited. The current recommended first-line H. pylori eradication regimens in children are mainly triple therapies consisting of a PPI plus two antibiotics chosen from Amoxicillin (AMX) or Clarithromycin (CLT or CLR) and Metronidazole (MTZ) for 14 days [7,8]. Levofloxacin (LVF or LEV) has restricted use in the pediatric age group due to safety concerns. On the other hand, Fluoroquinolones remain the drug of choice for specific indications, but their usage should be avoided in the presence of an alternative agent in children [9]. However, the eradication rate of these regimens has been less than 50%, especially among children [1]. On the other hand, many factors are responsible for eradication failure, starting with bacterial contamination, bacterial virulence, the CYP2C19 phenotype, patient compliance, and the most crucial factor: antibiotic resistance [10].
Given the limited number of antibiotics that are appropriate for H. pylori eradication in children, and the worldwide increase in antibiotic resistance, the recent European Society for Pediatric Gastroenterology Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN/NASPGHAN) have recommended antimicrobial susceptibility testing to guide H. pylori eradication treatment in children [7,11]. However, due to the fastidious culture of H. pylori and the lack of an easy and cost-effective testing method, antimicrobial susceptibility testing for H. pylori is almost universally unavailable in medical centers [12,13,14,15,16]. Under such circumstances, profiling regional or population-specific antibiotic resistance patterns is crucial in guiding the development of effective empiric treatment regimens. As the H. pylori antibiotic resistance profiles among children and adolescents in Jordan are lacking, the aim of this study was to evaluate H. pylori strains isolated from this population for antibiotic resistance to CLR, MTZ, and LEV.

2. Results

2.1. Characteristics of Study Participants

Between January 2018 and June 2019, 116 children and adolescents were referred to pediatric gastroenterology clinics and underwent gastrointestinal endoscopy to rule out H. pylori infectious gastritis. A total of 52 (44.8%) males and 64 (55.2%) females were included in this study. Of these, 64 (55.2%) and 59 (50.9%) were between 10 and 14 years of age when conducting this study and at the time of diagnosis, respectively. A total of 90 (77.6%) children presented with chronic abdominal pain where vomiting was the presenting symptom in 20 (17.2%) children and refractory anemia was the presenting symptom in 9 (7.8%) children (Table 1).
In total, 106 (89.7%) children in the study population did not have a family history of H. pylori infection. Eighteen (15.5%) patients had taken at least one eradication course before undergoing endoscopy in our department, whereas ninety-six (82.7%) were naïve to eradication therapy. A total of 29 (25%) patients confirmed ever using an antibiotic: 10 (8.6%) patients used MTZ, 9 (7.7%) used a macrolide, 3 (2.5%) used MTZ and a macrolide, and 7 (6%) used other types of antibiotics (Table 1).
All of our patients underwent endoscopy, and RUT was positive in 109 (93.9%). It was negative in 4 (3.4%) patients, and it was not conducted in 3 (2.7%) patients. Histological examination of biopsies revealed severe gastritis in around 28 (24.1%) patients, while moderate gastritis was the predominant finding in 52 (44.8%) patients. H. pylori was found in 104 patients’ biopsies (89.6%) (Table 1).

2.2. H. pylori Management and Follow Up

Of all patients, 103 (88.9%) had AMX, CLT, and PPI as their first eradication therapy. In comparison, 3 (2.6%) had AMX, CLT, and MTZ as the antibiotic part of their eradication therapy (Table 2).
Forty-six (39.6%) patients were followed for one to six months. Seventy-eight (67.2%) were compliant with their treatment. We assessed the success of the first eradication therapy in 52 (44.8%) patients by evaluating symptoms and testing for H. pylori antigen in their stool. A total of 25 (21.6%) patients had positive H. pylori antigen in their stool after the first eradication therapy, whereas 27 (23.3%) patients had negative results. Of the total study population, 34 (29.3%) lost follow-up after the first eradication therapy (Table 2).
Twenty-six (22.4%) children of those who followed up needed second eradication therapy; eleven (9.5%) were given AMX, CLT, and MTZ. LVF and AMX were given as a second eradication therapy in 4 (3.4%) patients. Six (5.2%) patients were assessed for the success of the second eradication therapy; stool antigen was done in three (2.6%) of them and was positive in two (1.7%) patients (Table 2).

2.3. H. pylori Antimicrobial Resistance

There were 71 (61.2%) positive H. pylori cultures; 30 (42.3%) of them were resistant to CLT, 58 (81.7%) were resistant to MTZ, and 8 (11.3%) were resistant to LVF. Resistance was assessed using E-test MIC data. On the other hand, there were 38 (53.5%) cultures with combined resistance. A total of 26 (68.4%) cultures with combined resistance were resistant to CLT and MTZ, 7 (18.4%) were resistant to MTZ and LEV, 3 (7.9%) positive cultures were resistant to LEV and CLT, and 2 (5.3%) cultures were resistant to the 3 antibiotics studied: CLT, MTZ, and LEV (Table 3).
DNA was extracted from 66 (92.9%) positive H. pylori culture plates and 50 (48.1%) positive H. pylori biopsies. An RT-PCR kit used specific urease gene primers (ureA and/or ureB) for H. pylori species identification relevant to its urease enzyme production and different primers for A2142G and A2143G in 23S rRNA operon for CLT resistance. Urease genes for H. pylori identifications using RT-PCR were documented in 97/115 (84.3%) extracted DNA samples. A2142G and/or A2143G mutations related to CLA resistance were documented using RT-PCR in 30/115 (26.1%) specimens (Table 4).
LEV resistance was confirmed in 6/114 (5.3%) samples using DNA sequencing of the quinolone resistance-determining region (QRDR) of the gyrA gene (Table 4). Various substitutions were observed in the QRDR region of the gyrA gene, including four mutations corresponding to Asp-91 and two mutations corresponding to Asn-87. We also found two resistant strains with no QRDR mutations (Table 5).

2.4. Factors Associated with Failure of First Eradication Therapy or Antibiotics Resistance

Weight loss and abdominal pain as presenting symptoms were significantly associated with the failure of the first eradication therapy (p values 0.028 and 0.037, respectively). The previous eradication trial without complete diagnostics was significantly associated with the failure of the first eradication course (p value 0.011). Resistance to CLT detected by RT-PCR with a positive mutation was significantly associated with the failure of the first eradication therapy (p value 0.01) (Table 6).
Children between 10 and 14 years of age had the highest CLT resistance rate compared to other age groups (56.7%). No significant difference was found in resistance rates to MTZ, LEV, and CLT among the three age groups. The percentage of females with resistant strains to the three antibiotics studied, CLT, MTZ, and LEV, was higher (56.7%, 56.9%, 62.5%, respectively) (Table 7).
Antibiotic resistance in H. pylori was significantly correlated with specific presenting symptoms. Abdominal pain was significantly associated with MTZ resistance (p value 0.034). Refractory anemia was associated significantly with CLT and LVF resistance (p values 0.048 and 0.018, respectively). On the other hand, hematemesis was significantly associated with CLT, MTZ, and LEV resistance (p values 0.003, 0.007, and 0.007, respectively) (Table 7).
A total of 100% of the strains resistant to LVF were found in H. pylori treatment-naïve children. The 34 strains isolated from patients with prior H. pylori treatment were more likely to be resistant to CLR than the 53 strains isolated from H. pylori treatment-naïve patients (70.6 vs. 45.3%, p = 0.02). However, no significant difference was observed between patients with a previous history of antibiotic use and resistant rates to MTZ and LEV (Table 7).
Twenty-six children (44.8%) had combined resistance to both CLT and MTZ, while three (37.5%) had combined resistance to CLT and LEV. A total of 26 patients (86.7% of patients with CLT resistance) and 7 patients (87.5% of patients with LVF resistance) had resistance to MTZ. The severity of histological findings in biopsies was significantly associated with resistance in all three antibiotics: CLT, MTZ, and LEV (p values 0.008, 0.005, and 0.01, respectively) (Table 7).

3. Discussion

The success of eradication therapy depends mainly on the antibacterial resistance pattern in a specific investigated population. Eradication failure can increase the risk of H. pylori resistance as well as burden patients with unnecessary extra procedures and increase healthcare utilization [17]. Primary CLT resistance has increased above the recommended levels (15%) for use as a first-line anti-H. pylori agent, demanding the use of regional antibiotic resistance data to govern its management [6,18].
This is the first longitudinal prospective study on H. pylori in Jordanian children. This fastidious microorganism was cultured, and its antimicrobial susceptibility was studied using phenotypic and molecular methods aiming at adding to the regional data on antimicrobial resistance in H. pylori to aid in the management of H. pylori gastritis in children.
H. pylori gastritis is the most common cause of gastritis and peptic ulcer disease worldwide. The infection is prevalent and increases with age. About 50% of the world’s population is estimated to have H. pylori infection [19,20]. Due to the variety of risk factors present in developing countries, infection with multiple H. pylori genotypes is highly prevalent in the Middle East and North Africa (MENA) region. The prevalence of H. pylori infection among the countries of the MENA region varies widely, ranging from 7 to 50% in young children and going up to 36.8–94% in adults [21], 86% in Saudi Arabia [22], and 70–82% in Jordan [23,24]. Limited data are available for the prevalence rate among pediatrics. H. pylori in gastric mucosa among pediatric patients who had endoscopy at Prince Hamzah Hospital was about 90% in this study. After reviewing reports from the last 10 years, it has been noticed that this percentage is consistent with data from many European countries, including France [25], Italy [26,27], Spain [28,29], and Portugal [30], and concurrent with the multicenter study on H. pylori primary resistance in Europe from 2013 [17].
This study shows a significant correlation between the presence of histological gastritis and H. pylori infection, especially for the moderate histological gastritis group, in agreement with previous studies [23,31]. Abdominal pain and weight loss were associated [12,14,32] with the failure of the first eradication therapy. Meanwhile, previous eradication therapy and CLT resistance significantly increased the risk of first-line therapy failure, which is consistent with the literature [33,34]. In this study, the H. pylori positivity rate was 93.9%, 89.6%, 84.3%, and 61.7% according to RUT, histology, RT-PCR, and culture, respectively. Other studies have shown similarly low rates for H. pylori culture due to its fastidious and demanding nature [12,13,14].
Among children, many global studies reported an increased incidence of primary antibiotic-resistant H. pylori strains [35]. The overall resistance rates in one study were 55.2% for CLT, 71.3% for MTZ, 60.9% for Rifampicin (RIF), and 18.4% for LVF [36].
The antimicrobial susceptibility test results of all H. pylori strains shown in Table 3 report a resistance rate in MTZ around 50% and 26% and 7% in CLT and LEV, respectively. Merei et al. showed resistance to MTZ in 32/46 isolates (69.5%), to CLT in 10 (21.7%), and to LEV in 3 (6.9%) [37]. Kalach et al. reported antimicrobial resistance in Iranian children as follows: MTZ, 62%; CLA, 22%; AMO, 16%; and LEV, 5.3% [38]. In Poland, the primary resistance of H. pylori indicates a persistently high level of CLT and MTZ resistance in both children and adults [39]. Meanwhile, LEV resistance increased over the last decade from 1.9% to 9.1% in pediatric patients and from 11.7% to 18.4% in adults [26]. This is in line with reports from another research center in Poland, indicating an increasing resistance of H. pylori strains to LEV [40]. Amoxicillin use is common among first-line therapy studied and evaluated by many investigations in adult and pediatric populations, and its resistance remains low. On the other hand, even though Levofloxacin has limited use in the pediatric age group due to safety concerns, it has specific indications as a “last resort” antibiotic after failures of other therapy lines. Multiple recent studies on antibiotic resistance in H. pylori gastritis in children have shown emerging levofloxacin resistance, which warrants investigation and more profound research. Recommendations regarding using levofloxacin in children have varied widely. Children resistant to levofloxacin will likely carry resistance that will mediate therapy failure in adulthood. Levofloxacin use in adults is becoming more common due to resistance to fist-line therapy. Many other studies conducted in children have also evaluated H. pylori’s resistance to Levofloxacin [34,37].
A2143G and/or A2142G mutation of 23S rRNA are the most common mediators of CLT resistance in H. pylori [37,39,40,41]. Similar findings were observed in this study.
Specific mutations in the genes encoding DNA gyrase and/or topoisomerase IV cause fluoroquinolone resistance [42]. Mutations in the DNA gyrase gene have been assumed to be the origin of fluoroquinolone resistance in H. pylori caused mainly by point mutations in the QRDR of the gyrA/B gene [43]. There have been reports of gyrA mutations at Asn-87 and Asp-91 in the past [44,45]. We report mutations at Asp-91 in four resistant strains (50%) and mutations at Asn-87 in two resistant strains (25.0%). However, neither strain had both Asp-91 and Asn-87 mutations simultaneously. Mutations at Asp-91 were more frequent than at Asn-87. These findings are in accordance with earlier reports from Hong Kong and Vietnam, contrary to reports from Japan and China, indicating a correlation between geographical differences [45,46,47,48]. In this study, two resistant strains had no mutations in the QRDR of the gyrA gene but exhibited elevated MICs of fluoroquinolone antibiotics. This could be due to other mutations in the non-QRDRs of the gyrA or the less frequent gyrB gene, or other mechanisms, such as multidrug efflux systems [48,49].

4. Materials and Methods

4.1. Subjects

Children between one and fourteen years of age were referred to the pediatric gastrointestinal clinic at Prince Hamzah Hospital (PHH) from January 2018 to June 2019. Their presenting symptoms or laboratory findings suggested either H. pylori gastritis or peptic ulcer disease. Subjects were included in the study if they underwent Esophagogastroduodenoscopy (EGD), and a Rapid Urease Test (RUT) was performed during EGD and biopsies for histopathology and culture were taken. Children were excluded if they were older than 15 years at the time of EGD, had a severe systemic illness, were on PPI or antibiotics in the last month, or had previous gastric surgery.

4.2. H. pylori Diagnosis and Management

During EGD, six antral and two fundal gastric biopsies were obtained. The first two biopsies (one forceps pass) were used for culture, the second two biopsies were used for RUT, and the last four biopsies were used for histology [15]. A RUT was performed using a commercial kit (Helicotec UT plus, Taiwan). A color change from yellow to pink observed up to 4 h after the end of EGD indicated a positive result at 37 °C.
Based on ESPGHAN/NASPGHAN guidelines, pediatric gastroenterologists diagnosed H. Pylori gastritis when tissue culture was positive for H. pylori or H. pylori was present in gastric mucosa in combination with a positive RUT.
A negative H. pylori status was confirmed when histology and culture were negative. The 2016 ESPGHAN/NASPGHAN guidelines were followed to determine medical management regimens and dosages [7,11]. The treating physicians investigated and confirmed compliance with therapy.

4.3. H. pylori Identification and Antimicrobial Susceptibility Testing

Gastric biopsies collected from the antra and corpora of the patients were placed in sterile vials containing Stuart’s transport medium without charcoal (Biolab, Hungary) and transferred on ice to the Microbiology laboratory at the Faculty of Medicine at the Hashemite University. Biopsy tissues were homogenized, grounded using a tissue homogenizer (TissueLyser LT, Qiagen, Hilden, Germany), and inoculated into Columbia blood agar base (Oxoid, UK). This base contained 10% sheep blood and H. pylori selective supplement (Oxoid, UK) to inhibit the growth of other contaminant microorganisms. Plates were incubated at 37 °C and 5% CO2 in a CO2 incubator (Heracell™ 150i CO2, Waltham, MA, USA) for two weeks. Colonies displaying typical H. pylori morphology on agar were confirmed via Gram-staining, positive urease, catalase, and oxidase tests. The original biopsy samples and those that yielded positive H. pylori growth were stored in broth with 20% glycerol at –80 °C for further analysis.
Two MacFarland’s standards of bacterial suspension were prepared and spread on solid agar media. Minimal Inhibition Concentration (MIC) was determined after incubation of plates for 5–7 days under proper conditions. H. pylori strains were tested for susceptibility to CLR, MTZ, and LEV using the Epsilometer test (E-test) strips (bioMérieux, Marcy-l’Étoile, France). According to the European Committee on Antimicrobial Susceptibility Testing [EUCAST], H. pylori resistance to CLR, MTZ, and LEV was defined as the MIC > 0.5 mg/L, >8 mg/L, and >1 mg/L, respectively [16].

4.4. Molecular Analysis of H. pylori and Antibiotics Resistance Genes

H. pylori genomic DNA was extracted and purified from biopsy samples or pure H. pylori colonies using a DNeasy Blood & Tissue extraction kit according to manufacturer instructions (Qiagen, Germany). Specific identification of H. pylori and detection of CLR resistance were performed using a Real-Time PCR (RT-PCR) detection Kit according to manufacturer instructions (VIASURE H. pylori + CLT resistance, Certest Biotec, Zaragoza, Spain). The kit uses specific urease genes (ureA and ureB) for H. pylori identifications and uses two major mutations, A2142G and A2143G, in 23S rRNA operon for CLT resistance.
To determine the gyrA mutations, we amplified and sequenced the quinolone resistance-determining region (QRDR) of the gyrA gene. Primers used were gyrAF (5′-TTTRGCTTATTCMATGAGCGT-3′) and gyrAR (5′-GCAGACGGCTTGGTARAATA-3′). PCR was performed in a 50 μL reaction volume containing 2 μL of the template DNA and 2.5 U of OneTaq DNA Polymerase (New England Biolabs, Hitchin, UK). Thermocycling conditions were 94 °C for 5 min, followed by 35 cycles of 94 °C for 30 s, 53 °C for 30 s, and 72 °C for 30 s, with a final extension step of 72 °C for 10 min.
The reaction products were checked and visualized by running 5 μL of the reaction mixture on 1% agarose gels. Sequencing of the amplified DNA was performed by the sequencing division at Princess Haya Biotechnology Center, University of Science and Technology, Irbid, Jordan. The sequences were then compared with the published sequence of the H. pylori gyrA gene (GenBank accession number L29481).
Informed consent was obtained from the patients’ parents or guardians. The IRB committee at The Hashemite University and the Jordan Ministry of Health/PHH approved this study.

4.5. Statistical Analysis

Data was recorded and coded in Microsoft Excel 365 and then exported to Statistical Package for the Social Sciences (SPSS) version 25 for further analysis (IBM, Armonk, NY, USA, 2017). Categorical variables were presented as frequencies (numbers) and percentages (%). Continuous variables were further stratified into categories and presented as frequencies and percentages. Factors associated with failure of first eradication therapy and the presence of antibiotic resistance were analyzed using Chi-squared or Fisher’s exact test as appropriate, and p values less than 0.05 were considered significant.

5. Conclusions

This study provided important updates regarding H. pylori prevalence, antibiotic resistances rates, and significant risk factors for eradication treatment failure among Jordanian children. Drug-resistant H. pylori rates are increasing at an alarming rate that should be considered by treating physicians when planning eradication therapy. H. pylori resistance was documented for commonly used first-line eradication therapy associated with therapy failure and the required consideration of other treatment options. While H. pylori culture and antibiotic susceptibility are helpful tools in guiding treatment, technical difficulties and low success rate compromise their routine use to guide treatment. RT-PCR for H. pylori identification and microbial resistance determination are valuable alternatives. A regional antibiotic resistance profile for the population will help develop effective local eradication regimens.

Author Contributions

Substantial contributions to the conception: S.B., M.B. (Maha Barbar) and M.A.-T. Study design: S.B. and M.A.-T. Data-acquisition: M.A.-T., J.A.-R., H.A., N.H. and M.S.M. Data analysis: M.A.-T. Data interpretation: A.I.K. Manuscript drafting: S.B. and M.A.-T. Manuscript revision: A.I.K. and M.B. (Mohammad Barqawi). All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Scientific Research Deanship Grant, The Hashemite University, Zarqa, Jordan.

Institutional Review Board Statement

The IRB committee at The Hashemite University and the Jordan Ministry of Health/PHH approved this study.

Informed Consent Statement

Informed consent was obtained from the patients’ parents or guardians.

Data Availability Statement

Data is available from authors upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Van Thieu, H.; Duc, N.M.; Nghi, B.T.D.; Van Bach, N.; Khoi, H.H.; Tien, V.N.T.; Bang, M.T.L.; Ngoc, T.L.C. Antimicrobial Resistance and the Successful Eradication of Helicobacter pylori-Induced Gastroduodenal Ulcers in Vietnamese Children. Med. Arch. 2021, 75, 112–115. [Google Scholar] [CrossRef] [PubMed]
  2. Malfertheiner, P.; Megraud, F.; O’Morain, C.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017, 66, 6–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Shu, X.; Yin, G.; Liu, M.; Peng, K.; Zhao, H.; Jiang, M. Antibiotics resistance of Helicobacter pylori in children with upper gastrointestinal symptoms in Hangzhou, China. Helicobacter 2018, 23, e12481. [Google Scholar] [CrossRef]
  4. Cardos, I.A.; Zaha, D.C.; Sindhu, R.K.; Cavalu, S. Revisiting therapeutic strategies for H. Pylori treatment in the context of antibiotic resistance: Focus on alternative and complementary therapies. Molecules 2021, 26, 6078. [Google Scholar] [CrossRef]
  5. Saito, H.; Nishikawa, Y.; Masuzawa, Y.; Tsubokura, M.; Mizuno, Y. Helicobacter pylori Infection Mass Screening for Children and Adolescents: A Systematic Review of Observational Studies. J. Gastrointest. Cancer 2021, 52, 489–497. [Google Scholar] [CrossRef] [PubMed]
  6. Biernat, M.M.; Iwańczak, B.; Bińkowska, A.; Grabińska, J.; Gościniak, G. The Prevalence of Helicobacter pylori Infection in Symptomatic Children: A 13-Year Observational Study in the Lower Silesian Region. Adv. Clin. Exp. Med. 2016, 25, 303–308. [Google Scholar] [CrossRef] [Green Version]
  7. Jones, N.L.; Koletzko, S.; Goodman, K.; Bontems, P.; Cadranel, S.; Casswall, T.; Czinn, S.; Gold, B.D.; Guarner, J.; Elitsur, Y.; et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J. Pediatr. Gastroenterol. Nutr. 2017, 64, 991–1003. [Google Scholar] [CrossRef]
  8. Tong, Y.F.; Lv, J.; Ying, L.Y.; Xu, F.; Qin, B.; Chen, M.T.; Meng, F.; Tu, M.Y.; Yang, N.M.; Li, Y.M.; et al. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance. World J. Gastroenterol. 2015, 21, 13073–13079. [Google Scholar] [CrossRef]
  9. Wang, J.G.; Cui, H.R.; Hu, Y.; Sen Tang, H.B. Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis. Medicine 2020, 99, e21860. [Google Scholar] [CrossRef]
  10. Graham, D.Y.; Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59, 1143–1153. [Google Scholar] [CrossRef]
  11. Burayzat, S.; Odeh, M.; Altamimi, E.; Al-Dweik, S.; El Wahab, K.; Alanasweh, M.; Al-Khraisat, M.; Barqawi, M. Eesophagogastroduodenoscopy in paediatrics: Does abiding by the international guidelines lead to appropriate management? A cross-sectional study. BMJ Open 2022, 12, e061489. [Google Scholar] [CrossRef]
  12. Montes, M.; Pérez-Trallero, E. How long until routine Helicobacter pylori antimicrobial susceptibility testing? Lancet Infect. Dis. 2017, 17, 130–131. [Google Scholar] [CrossRef]
  13. Li, H.; Yang, T.; Tang, H.; Tang, X.; Shen, Y.; Benghezal, M.; Tay, A.; Marshall, B. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed. Precis. Clin. Med. 2019, 2, 77–80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Tang, X.; Shen, Y.; Hu, R.; Yang, T.; Benghezal, M.; Li, H.; Tang, H. Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori. Helicobacter 2020, 25, e12703. [Google Scholar] [CrossRef]
  15. Megraud, F.; Coenen, S.; Versporten, A.; Kist, M.; Lopez-Brea, M.; Hirschl, A.M.; Andersen, L.P.; Goossens, H.; Glupczynski, Y.; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62, 34–42. [Google Scholar]
  16. Nyssen, O.P.; Bordin, D.; Tepes, B.; Pérez-Aisa, Á.; Vaira, D.; Caldas, M.; Bujanda, L.; Castro-Fernandez, M.; Lerang, F.; Leja, M.; et al. European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients. Gut 2021, 70, 40–54. [Google Scholar] [CrossRef]
  17. Naja, F.; Kreiger, N.; Sullivan, T. Helicobacter pylori Infection in Ontario: Prevalence and Risk Factors. Can. J. Gastroenterol. 2007, 21, 501–506. [Google Scholar] [CrossRef] [Green Version]
  18. Molaoa, S.Z. Prevalence of Helicobacter pylori infection and the incidence of the associated malignant and peptic ulcer disease (PUD) at Nelson Mandela Academic Hospital: A retrospective analysis. J. Drug Assess. 2021, 10, 57–61. [Google Scholar] [CrossRef] [PubMed]
  19. Alsulaimany, F.A.S.; Awan, Z.A.; Almohamady, A.M.; Koumu, M.I.; Yaghmoor, B.E.; Elhady, S.S.; Elfaky, M.A. Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina 2020, 56, 169. [Google Scholar] [CrossRef] [Green Version]
  20. Bakri, M.M. Prevalence of Helicobacter pylori infection and the incidence of ureA and clarithromycin resistance gene 23S rRNA genotypes status in Saudi Arabia. Saudi J. Biol. Sci. 2013, 20, 75–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Bani-Hani, K.M.H.S. Prevalence of Helicobacter pylori in Northern Jordan. Endoscopy based study. Saudi Med. J. 2001, 22, 843–847. [Google Scholar] [PubMed]
  22. Altamimi, E.; Alsharkhat, N.; AlJawarneh, A.; Abu Hamad, M.R.; Abu Assi, A.; Alawneh, S.; Al-Ahmad, M. Declining prevalence of Helicobacter pylori infection in Jordanian children, report from developing country. Heliyon 2020, 6, e04416. [Google Scholar] [CrossRef] [PubMed]
  23. Ducournau, A.; Bénéjat, L.; Sifré, E.; Bessède, E.; Lehours, P.; Mégraud, F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin. Microbiol. Infect. 2016, 22, 715–718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Saracino, I.M.; Fiorini, G.; Zullo, A.; Pavoni, M.; Saccomanno, L.; Vaira, D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics 2020, 9, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Fiorini, G.; Zullo, A.; Saracino, I.M.; Pavoni, M.; Vaira, D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016. Scand. J. Gastroenterol. 2018, 53, 661–664. [Google Scholar] [CrossRef] [PubMed]
  26. Morilla, A.M.; Álvarez-Argüelles, M.E.; Duque, J.M.; Armesto, E.; Villar, H.; Melón, S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol. Hepatol. 2019, 42, 476–485. [Google Scholar] [CrossRef]
  27. Macías-García, F.; Llovo-Taboada, J.; Díaz-López, M.; Bastón-Rey, I.; Domínguez-Muñoz, J.E. High primary antibiotic resistance of Helicobacter pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter 2017, 22, e12440. [Google Scholar] [CrossRef]
  28. Almeida, N.; Romãozinho, J.; Donato, M.; Luxo, C.; Cardoso, O.; Cipriano, M.; Marinho, C.; Fernandes, A.; Calhau, C.; Sofia, C. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clin. Microbiol. Infect. 2014, 20, 1127–1133. [Google Scholar] [CrossRef] [Green Version]
  29. Ghasemi Basir, H.R.; Ghobakhlou, M.; Akbari, P.; Dehghan, A.; Seif Rabiei, M.A. Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis. Gastroenterol. Res. Pract. 2017, 2017, 8320496. [Google Scholar] [CrossRef] [Green Version]
  30. Tseng, D.S.; Li, D.; Cholleti, S.M.; Wei, J.C.; Jodesty, Y.; Pham, H.-V. Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia. Perm. J. 2019, 23, 18–195. [Google Scholar] [CrossRef] [Green Version]
  31. Zhang, M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J. Gastroenterol. 2015, 21, 13432–13437. [Google Scholar] [CrossRef] [PubMed]
  32. Nestegard, O.; Moayeri, B.; Halvorsen, F.-A.; Tønnesen, T.; Sørbye, S.W.; Paulssen, E.; Johnsen, K.-M.; Goll, R.; Florholmen, J.R.; Melby, K.K. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS ONE 2022, 17, e0265322. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, L.; Zhang, J.; Hu, M.; Pang, X. Comparison of Drug Resistance of Helicobacter pylori Between Children and Adults in Jilin, China. Turk. J. Gastroenterol. 2021, 32, 1012–1018. [Google Scholar] [CrossRef]
  34. Li, J.; Deng, J.; Wang, Z.; Li, H.; Wan, C. Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric Patients in Southwest China. Front. Microbiol. 2021, 11, 621791. [Google Scholar] [CrossRef] [PubMed]
  35. Marie, M.A.M. Patterns of Helicobacter pylori Resistance to Metronidazole, Clarithormycin and Amoxicillin in Saudi Arabia. J. Bacteriol. Virol. 2008, 38, 173–178. [Google Scholar] [CrossRef] [Green Version]
  36. Kalach, N.; Bontems, P.; Raymond, J. Helicobacter pylori infection in children. Helicobacter 2017, 22, 1–7. [Google Scholar] [CrossRef] [PubMed]
  37. Gościniak, G.; Biernat, M.; Grabińska, J.; Bińkowska, A.; Poniewierka, E.; Iwańczak, B. The Antimicrobial Susceptibility of Helicobacter pylori Strains Isolated from Children and Adults with Primary Infection in the Lower Silesia Region, Poland. Pol. J. Microbiol. 2014, 63, 57–61. [Google Scholar] [CrossRef]
  38. Karczewska, E.; Klesiewicz, K.; Skiba, I.; Wojtas-Bonior, I.; Sito, E.; Czajecki, K.; Zwolińska-Wcisło, M.; Budak, A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterol. Res. Pract. 2012, 2012, 418010. [Google Scholar] [CrossRef] [Green Version]
  39. Albasha, A.M.; Elnosh, M.M.; Osman, E.H.; Zeinalabdin, D.M.; Fadl, A.A.M.; Ali, M.A.; Altayb, H.N. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiol. 2021, 21, 38. [Google Scholar] [CrossRef]
  40. Correia, S.; Poeta, P.; Hébraud, M.; Capelo, J.L.; Igrejas, G. Mechanisms of quinolone action and resistance: Where do we stand? J. Med. Microbiol. 2017, 66, 551–559. [Google Scholar] [CrossRef]
  41. Mannion, A.; Dzink-Fox, J.; Shen, Z.; Piazuelo, M.B.; Wilson, K.T.; Correa, P.; Peek, R.M.; Camargo, M.C.; Fox, J.G. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J. Clin. Microbiol. 2021, 59, e03203-20. [Google Scholar] [CrossRef]
  42. Kim, S.E.; Park, M.I.; Park, S.J.; Moon, W.; Choi, Y.J.; Cheon, J.H.; Kwon, H.J.; Ku, K.H.; Yoo, C.H.; Kim, J.H.; et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J. Intern. Med. 2015, 30, 801–807. [Google Scholar] [CrossRef] [PubMed]
  43. Miyachi, H.; Miki, I.; Aoyama, N.; Shirasaka, D.; Matsumoto, Y.; Toyoda, M.; Mitani, T.; Morita, Y.; Tamura, T.; Kinoshita, S.; et al. Primary Levofloxacin Resistance and gyrA/B Mutations Among Helicobacter pylori in Japan. Helicobacter 2006, 11, 243–249. [Google Scholar] [CrossRef] [PubMed]
  44. Lee, C.C.; Lee, V.W.; Chan, F.K.; Ling, T.K. Levofloxacin-Resistant Helicobacter pylori in Hong Kong. Chemotherapy 2007, 54, 50–53. [Google Scholar] [CrossRef] [PubMed]
  45. Phan, T.N.; Santona, A.; Tran, V.H.; Tran, T.N.H.; Le, V.A.; Cappuccinelli, P.; Rubino, S.; Paglietti, B. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. Int. J. Antimicrob. Agents 2015, 45, 244–248. [Google Scholar] [CrossRef] [PubMed]
  46. Zhang, Y.; Wen, Y.; Xiao, Q.; Zheng, W.; Long, G.; Chen, B.; Shu, X.; Jiang, M. Mutations in the Antibiotic Target Genes Related to Clarithromycin, Metronidazole and Levofloxacin Resistance in Helicobacter pylori Strains from Children in China. Infect. Drug Resist. 2020, 13, 311–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Wang, L.H.; Cheng, H.; Hu, F.L.; Li, J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J. Gastroenterol. 2010, 16, 2272–2277. [Google Scholar] [CrossRef]
  48. Langner, M.; Machado, R.S.; Patrício, F.R.S.; Kawakami, E. Evaluation of gastric histology in children and adolescents with Helicobacter pylori gastritis using the Update Sydney System. Arq. Gastroenterol. 2009, 46, 328–332. [Google Scholar] [CrossRef] [Green Version]
  49. Kahlmeter, G.; Brown, D.; Goldstein, F.; MacGowan, A.; Mouton, J.; Odenholt, I.; Rodloff, A.; Soussy, C.-J.; Steinbakk, M.; Soriano, F.; et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin. Microbiol. Infect. 2006, 12, 501–503. [Google Scholar] [CrossRef] [Green Version]
Table 1. Characteristics of patients.
Table 1. Characteristics of patients.
CategoryVariableNumberPercentage (%)
DemographicsAge (years)0–597.8
5.1–104337.1
10.1–146455.2
GenderMale5244.8
Female6455.2
SymptomsAbdominal pain9077.6
Vomiting2017.2
Diarrhea1311.2
Weight loss97.8
Anemia97.8
Hematemesis97.8
Heartburn76
Flatulence32.6
Family history of H. pyloriPresent not documented10.9
Present and treated without endoscopy10.9
Present and treated with endoscopy54.3
None10489.7
N/A54.3
Previous eradicationYes1815.5
No9682.7
Antibiotics useYes2925.0
MTZ108.6
Macrolide97.7
Macrolide + MTZ32.5
Other76
EndoscopyYes116100
Macroscopic involvement of Stomach11498.3
Macroscopic involvement of Duodenum2521.6
Rapid Urease TestPositive10993.9
Negative43.4
N/A32.5
HistologyNormal10.9
Mild2925.0
Moderate5244.8
Severe2824.1
N/A65.2
H. pyloriin HistologyYes10489.6
No97.8
N/A32.6
H. pyloriculturePositive7161.2
Negative3731.9
N/A86.9
N/A: Not available, MTZ: Metronidazole.
Table 2. H. pylori management and follow up.
Table 2. H. pylori management and follow up.
CategoryVariableNumberPercentage (%)
First eradication therapyPPI + AMX + CLT10388.9
PPI + AMX + MTZ10.9
PPI + MTZ + CLT21.7
PPI + AMX + CLT + MTZ32.6
N/A76.0
Duration of follow-up (months)˂13025.9
1–64639.6
7–1265.2
The patient did not follow up3429.3
Compliance with treatmentYes7867.2
No43.4
Assessment of first eradicationResolution of symptoms2319.8
H. pylori antigen in stool76.0
Symptoms resolution + stool H. pylori antigen5244.8
H. pyloriantigen in stool after first eradicationPositive2521.6
Negative2723.3
Not done3026.3
Cause for the second courseRecurrence of symptoms97.8
Positive stool H. pylori antigen 1613.8
Second eradication therapyYes2622.4
PPI + AMX + CLT43.4
PPI + AMX + MTZ43.4
PPI + MTZ + CLT21.7
PPI + AMX + CLT + MTZ119.5
LVF + AMX43.4
Assessment of the second eradication courseDone and was negative for clearance10.9
Done and was positive for clearance21.7
Disappearance of symptoms32.6
N/A43.4
PPI: Proton pump inhibitor, AMX: Amoxicillin, MTZ: Metronidazole, CLT: Clarithromycin, LVF: Levofloxacin. N/A: Not available.
Table 3. Culture and antimicrobial susceptibility using E-test.
Table 3. Culture and antimicrobial susceptibility using E-test.
CategoryVariableNumberPercentage (%)
CultureGrowth7161.2
No growth3731.9
Contamination86.9
Resistant toCLTYes3042.3
No3650.7
N/A1318.3
Resistant to MTZYes5881.7
No811.3
N/A1318.3
Resistant to LVFYes811.3
No5881.7
N/A1318.3
Combined resistanceCLT + MTZ2668.4
MTZ + LVF78.4
CLT + LVF 37.9
LVF + MTZ + CLT25.3
AMX: Amoxicillin, MTZ: Metronidazole, CLT: Clarithromycin, LVF: Levofloxacin; N/A: Not available.
Table 4. DNA extraction and RT-PCR.
Table 4. DNA extraction and RT-PCR.
CategoryVariableNumberPercentage (%)
DNA extractionFrom H. pylori culture6656.9
From biopsy5043.1
H. pylori identification by RT-PCR Positive9784.3
Negative1815.7
Resistant to CLT by RT-PCRPositive3026.1
Negative8573.9
Resistant to LVF by DNA SequencingPositive65.3
Negative10894.7
RT: Real-time, PCR: Polymerase chain reaction.
Table 5. Amino acid changes in quinolone-resistant strains of H. pylori.
Table 5. Amino acid changes in quinolone-resistant strains of H. pylori.
StrainMutation of gyrA
1RAsp91Asn
2RNo QRDR mutation
3RAsn87Lys
4RAsp91Gly
5RAsp91Asn
6RAsp91Asn
7RNo QRDR mutation
8RAsn87Lys
Table 6. Factors associated with failure of first eradication therapy.
Table 6. Factors associated with failure of first eradication therapy.
CategoryVariablep Value
Demographics Age (years)0.635
Age at diagnosis (years)0.399
Gender0.263
Address0.319
Symptoms Abdominal pain0.037 *
Vomiting0.558
Flatulence0.406
Heartburn0.658
Weight loss0.028 *
Anemia0.682
Hematemesis0.682
Diarrhea0.489
Duration of symptoms (months) 0.148
Associated Medical diseases 0.635
Family history of H. pylori 0.466
Previous eradication 0.011 *
Antibiotics use 0.613
Resistant to CLT 0.061
Resistant to MTZ 0.747
Resistant to LVF 0.747
Resistant to CLT by RT-PCR with positive mutation0.010 *
RT: Real-time; PCR: Polymerase-chain reaction; * Significant p value < 0.05.
Table 7. Factors associated with the presence of antibiotic resistance.
Table 7. Factors associated with the presence of antibiotic resistance.
VariableCategoryCLR ResistanceMTZ ResistanceLEV Resistance
N%pN%pN%p
Age0–53100.97858.60.99000.99
5.1–101033.32034.5337.5
10.1–141756.73356.9562.5
GenderMale1343.30.8422543.10.63337.50.826
Female1756.73356.9562.5
Presenting symptomAbdominal pain2376.70.66947810.034 *787.50.57
Vomiting516.70.869915.50.896112.50.896
Flatulence26.70.3735.20.606000.606
Heartburn13.30.7446.90.921000.921
Weight loss3100.86610.30.759000.759
Anemia000.048 *23.40.08112.50.018 *
Hematemesis13.30.003 *58.60.007 *000.007 *
Diarrhea413.31712.11112.51
Previous eradicationYes724.90.5291119.30.686000.686
No2275.94680.78100
Duration of symptom˂13100.4231119.30.743114.30.955
1–61033.31424.6114.3
7–12723.31221.1342.9
˃129301729.8228.6
Incidental finding13.335.300
Family history of H. pyloriYes26.60.8848.60.4732250.271
No2893.35391675
Peptic ulcer diseaseYes000.31611.70.326000.326
No301005798.38100
Antibiotics useYes7250.1221527.30.1022250.127
No21754072.7675
Resistant to CLRYes---2644.80337.50
No--3255.2562.5
Resistant to MTZYes2686.70---787.50
No413.3--112.5
Resistant to LVFYes3100712.10---
No27905187.9--
Macroscopic involvement StomachYes2696.70.80581000.7681001.0
No13.30000
Macroscopic involvement DuodenumYes516.70.89211190.8432250.843
No2583.34781675
HistologyNormal000.008 *000.005 *000.010 *
Mild620111900
Moderate1653.33153.4562.5
Severe516.71220.7337.5
N/A31046.900
MTZ: Metronidazole, CLT and CLR: Clarithromycin, LEV and LVF: Levofloxacin. * Significant p value < 0.05.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Burayzat, S.; Al-Tamimi, M.; Barqawi, M.; Massadi, M.S.; Abu-Raideh, J.; Albalawi, H.; Khasawneh, A.I.; Himsawi, N.; Barber, M. Antimicrobial Resistance Molecular Mechanisms of Helicobacter pylori in Jordanian Children: A Cross-Sectional Observational Study. Antibiotics 2023, 12, 618. https://doi.org/10.3390/antibiotics12030618

AMA Style

Burayzat S, Al-Tamimi M, Barqawi M, Massadi MS, Abu-Raideh J, Albalawi H, Khasawneh AI, Himsawi N, Barber M. Antimicrobial Resistance Molecular Mechanisms of Helicobacter pylori in Jordanian Children: A Cross-Sectional Observational Study. Antibiotics. 2023; 12(3):618. https://doi.org/10.3390/antibiotics12030618

Chicago/Turabian Style

Burayzat, Salma, Mohammad Al-Tamimi, Mohammad Barqawi, Mustafa Sabri Massadi, Jumanah Abu-Raideh, Hadeel Albalawi, Ashraf I. Khasawneh, Nisreen Himsawi, and Maha Barber. 2023. "Antimicrobial Resistance Molecular Mechanisms of Helicobacter pylori in Jordanian Children: A Cross-Sectional Observational Study" Antibiotics 12, no. 3: 618. https://doi.org/10.3390/antibiotics12030618

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop